{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:14:24Z","timestamp":1766067264532,"version":"3.37.3"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Most patients receive systemic anticancer therapy (SACT) as day cases and toxicities, if they occur, are likely to appear first in primary care. Pharmaceutical care can be delivered by community pharmacists, but little is known about the epidemiology of SACT toxicities in the community and potential interventions to address these which raise the following questions: what are the typologies of SACT-associated toxicities experienced by community-based patients and what are the associated pharmaceutical care issues (PCIs)? The aim of this study was to identify toxicities and pharmaceutical care issues of patients prescribed SACT for lung cancer and understand the potential for community pharmacists to deliver aspects of cancer care including toxicity management.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Retrospective analysis of clinical records of patients prescribed oral and parenteral SACT in 2013\u201314, to describe patient characteristics; SACT toxicity; PCIs and episodes of unscheduled care.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>Twelve categories of toxicity and 13 categories of PCIs were identified from 50 patients. More PCIs were observed with oral SACT\/oral-parenteral combinations than with parenteral regimens. The PCIs which could be managed by community pharmacists were mucositis; skin toxicity; gastrointestinal toxicity; reinforcing patient education and identification\/prevention of drug interactions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Community pharmacists are ideally placed to provide pharmaceutical care to patients with lung cancer prescribed SACT. Cancer specialists in secondary care can signpost patients to community pharmacists for early management of low-grade SACT toxicity.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ijpp\/riaa008","type":"journal-article","created":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T04:13:21Z","timestamp":1609474401000},"page":"145-151","source":"Crossref","is-referenced-by-count":2,"title":["Pharmaceutical care issues in lung cancer: can community pharmacists support patients receiving systemic anticancer therapy?"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7744-7674","authenticated-orcid":false,"given":"Fiona M","family":"MacLean","sequence":"first","affiliation":[{"name":"NHS Greater Glasgow and Clyde, Scotland, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne C","family":"Boyter","sequence":"additional","affiliation":[{"name":"Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander B","family":"Mullen","sequence":"additional","affiliation":[{"name":"Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Lowrie","sequence":"additional","affiliation":[{"name":"Pharmacy Prescribing and Support Unit, Clarkston Court, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,12,10]]},"reference":[{"volume-title":"GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11","year":"2013","author":"Ferlay","key":"2021031710394077000_CIT0001"},{"volume-title":"Management of Lung Cancer","year":"2014","author":"SIGN137","key":"2021031710394077000_CIT0002"},{"volume-title":"The National Lung Cancer Audit Annual Report","year":"2015","key":"2021031710394077000_CIT0003"},{"key":"2021031710394077000_CIT0004","doi-asserted-by":"crossref","first-page":"226S","DOI":"10.1378\/chest.123.1_suppl.226S","article-title":"Chemotherapeutic management of stage IV non-small cell lung cancer","volume":"123","author":"Socinski","year":"2003","journal-title":"Chest"},{"key":"2021031710394077000_CIT0005","first-page":"9","article-title":"Pharmacists prescribers in cancer care: innovate, challenge and inspire","volume":"7","author":"MacLean","year":"2013","journal-title":"Eur J Oncol Pharm"},{"key":"2021031710394077000_CIT0006","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.2042-7174.2002.tb00593.x","article-title":"A classification system for issues identified in pharmaceutical care practice","volume":"10","author":"Krska","year":"2002","journal-title":"Int J Pharm Pract"},{"key":"2021031710394077000_CIT0007","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jpainsymman.2010.11.014","article-title":"Adverse drug reactions and drug interactions as causes of hospital admission in oncology","volume":"42","author":"Miranda","year":"2010","journal-title":"J Pain Symptom Manage"},{"key":"2021031710394077000_CIT0008","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1200\/JCO.2008.17.7162","article-title":"Chemotherapy in addition to supportive care improves survival in advanced non-small cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomised controlled trials","volume":"26","author":"Burdett","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021031710394077000_CIT0009","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1177\/1078155217732399","article-title":"Current models of support from community pharmacies for patients on anticancer medicines","volume":"25","author":"Dalby","year":"2019","journal-title":"J Oncol Pharm Practice"},{"key":"2021031710394077000_CIT0010","doi-asserted-by":"crossref","first-page":"e005674","DOI":"10.1136\/bmjopen-2014-005764","article-title":"The positive pharmacy care law: an area-level analysis of the relationship between community pharmacy distribution, urbanity and social deprivation in England","volume":"4","author":"Todd","year":"2014","journal-title":"BMJ Open"},{"volume-title":"Prescription for Excellence: A Vision and Action Plan","year":"2013","key":"2021031710394077000_CIT0011"},{"volume-title":"Detailed advice Document","year":"2006","author":"Erlotinib. No 220\/05","key":"2021031710394077000_CIT0012"},{"volume-title":"Pharmacy in the Future: Implementing the NHS Plan","year":"2000","author":"Department of Health","key":"2021031710394077000_CIT0013"},{"volume-title":"National Health Service (Scotland) ACT 1978 Health Board Additional Pharmaceutical Services (Minor Ailment Service) (Scotland) Directions","year":"2006","author":"Scottish Executive","key":"2021031710394077000_CIT0014"},{"key":"2021031710394077000_CIT0015","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1211\/ijpp.14.2.0009","article-title":"Design and evaluation of a documentation system to support the continuity of pharmaceutical care of day-case oncology patients between hospital and community pharmacists","volume":"14","author":"Fisher","year":"2006","journal-title":"Int J Pharm Pract"},{"volume-title":"Utilising Community Pharmacists to Support Patients With Cancer","year":"2020","key":"2021031710394077000_CIT0016"},{"key":"2021031710394077000_CIT0017","doi-asserted-by":"crossref","first-page":"e025114","DOI":"10.1136\/bmjopen-2018-025114","article-title":"Community pharmacy lifestyle intervention to increase physical activity and improve cardiovascular health of men with prostate cancer: a phase II feasibility study","volume":"9","author":"Lemanska","year":"2019","journal-title":"BMJ Open"},{"key":"2021031710394077000_CIT0018","first-page":"102","article-title":"Developing a patient pathway to deliver a new oral chemotherapy","volume":"19","author":"Deery","year":"2003","journal-title":"The Professional Nurse"},{"volume-title":"Summary of Product Characteristic","year":"2019","author":"Tarveva 100mg film coated tablets","key":"2021031710394077000_CIT0019"},{"key":"2021031710394077000_CIT0020","doi-asserted-by":"crossref","first-page":"42","DOI":"10.7748\/cnp.2018.e1525","article-title":"Can community pharmacy practitioners support patients who take oral anti-cancer medication? Patients\u2019 needs and views","volume":"18","author":"Dalby","year":"2018","journal-title":"Cancer Nursing Practice"},{"author":"NHS Greater Glasgow and Clyde","key":"2021031710394077000_CIT0021"},{"key":"2021031710394077000_CIT0022","first-page":"15","article-title":"An evaluation of the quality and nature of interventions made by oncology pharmacists at Guy\u2019s Cancer Centre","volume":"24","author":"Watkins","year":"2018","journal-title":"J Oncol Pharm Pract"},{"year":"2016","author":"Oakley","key":"2021031710394077000_CIT0023"},{"key":"2021031710394077000_CIT0024","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11096-010-9410-0","article-title":"Potential drug-drug interactions between anti-cancer agents and community pharmacy dispensed drugs","volume":"32","author":"Voll","year":"2010","journal-title":"Pharm World Sci"},{"key":"2021031710394077000_CIT0025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.7748\/cnp.2019.e1613","article-title":"Feasibility of a referral pathway to community pharmacy for patients taking oral anti-cancer medication","volume":"18","author":"Dalby","year":"2019","journal-title":"Cancer Nurs Pract"},{"key":"2021031710394077000_CIT0026","article-title":"How to support cancer patients in community pharmacies","volume":"298: 7899","author":"Lewis","year":"2017","journal-title":"Pharm J"},{"key":"2021031710394077000_CIT0027","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/1078155213504975","article-title":"Are community pharmacists equipped to ensure the safe use of oral anticancer therapy in the community setting? Results of a cross-country survey of community pharmacists in Canada","volume":"20","author":"Abbott","year":"2014","journal-title":"J Oncol Pharm Pract"},{"key":"2021031710394077000_CIT0028","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1331\/JAPhA.2008.07082","article-title":"Community pharmacists\u2019 knowledge of and attitudes toward oral chemotherapy","volume":"48","author":"O\u2019Bryant","year":"2008","journal-title":"J Am Pharm Assoc"}],"container-title":["International Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ijpp\/article-pdf\/29\/2\/145\/36622575\/riaa008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijpp\/article-pdf\/29\/2\/145\/36622575\/riaa008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T10:40:20Z","timestamp":1615977620000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijpp\/article\/29\/2\/145\/6025524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,10]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,12,10]]},"published-print":{"date-parts":[[2021,3,17]]}},"URL":"https:\/\/doi.org\/10.1093\/ijpp\/riaa008","relation":{},"ISSN":["0961-7671","2042-7174"],"issn-type":[{"type":"print","value":"0961-7671"},{"type":"electronic","value":"2042-7174"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2020,12,10]]}}}